Concepedia

Robert P. Lyon

RP

Statistics

Publications

31

Citations

3.3K

H-Index

24

Active since

1994

Affiliations

Seagen (United States)(Current)

University of Washington

Robert P. Lyon is an author at Seagen (United States) specializing in antibody-drug conjugates, pharmacy, and antibody conjugates.

ORCID

Publications per year

1994–2023

31

Publications

31

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

Robert P. Lyon, Tim D. Bovee, Svetlana O. Doronina et al. · Nature Biotechnology · 2015 · 523 citations

, , +14

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

Robert P. Lyon, Jocelyn R. Setter, Tim D. Bovee et al. · Nature Biotechnology · 2014 · 445 citations

, , +16

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey et al. · Blood · 2013 · 386 citations

, , +13

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models

Li Fu, Kim K. Emmerton, Mechthild Jonas et al. · Cancer Research · 2016 · 321 citations

, , +17

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

Scott C. Jeffrey, Patrick Burke, Robert P. Lyon et al. · Bioconjugate Chemistry · 2013 · 246 citations

, , +17

1–5 of 31